青蒿素及其衍生物在女性生殖系统恶性肿瘤中的研究进展
Research Progress of Artemisinin and Its Derivatives in Female Reproductive System Malignancies
DOI: 10.12677/md.2026.164058, PDF,   
作者: 王 晓：承德医学院研究生学院，河北 承德；邢台市人民医院妇科，河北 邢台；李艺博：承德医学院研究生学院，河北 承德；周 楠*：邢台市人民医院妇科，河北 邢台
关键词: 青蒿素及其衍生物；女性生殖系统恶性肿瘤；乳腺癌；Artemisinin and Its Derivatives； Female Reproductive System Malignancies； Breast Cancer
摘要: 青蒿素及其衍生物(Artemisinin and its derivatives, ARTs)目前主要应用于疟疾治疗。近年来，其抗肿瘤活性受到了广泛关注。多项研究已经证实ARTs能够通过抑制肿瘤细胞增殖、诱导细胞凋亡、阻滞细胞周期以及调节肿瘤微环境等多种途径，对乳腺癌、卵巢癌、宫颈癌和子宫内膜癌等女性生殖系统恶性肿瘤发挥抗肿瘤作用。并且ARTs能够逆转化疗耐药，与常规抗癌药物产生协同效应，这为临床耐药患者的治疗提供了新的思路。本文主要对青蒿素及其衍生物在女性生殖系统恶性肿瘤治疗中的研究进展进行综述，以期为女性生殖系统恶性肿瘤的治疗提供新思路。
Abstract: Artemisinin and its derivatives (ARTs) are currently primarily used in the treatment of malaria. In recent years, their antitumor activity has received widespread attention. Numerous studies have confirmed that ARTs can exert antitumor effects against female reproductive system malignancies, including breast cancer, ovarian cancer, cervical cancer, and endometrial cancer, through multiple mechanisms such as inhibiting tumor cell proliferation, inducing apoptosis, arresting the cell cycle, and regulating the tumor microenvironment. Moreover, ARTs can reverse chemotherapy resistance and produce synergistic effects with conventional anticancer drugs, providing new ideas for the treatment of clinically drug-resistant patients. This review summarizes the research progress of artemisinin and its derivatives in the treatment of female reproductive system malignancies, aiming to provide new insights for the treatment of these cancers.
文章引用：王晓, 李艺博, 周楠. 青蒿素及其衍生物在女性生殖系统恶性肿瘤中的研究进展[J]. 医学诊断, 2026, 16(4): 436-448. https://doi.org/10.12677/md.2026.164058

参考文献

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263.
https://doi.org/10.3322/caac.21834
[2] Xiang, Y., Guo, Z., Zhu, P., Chen, J. and Huang, Y. (2019) Traditional Chinese Medicine as a Cancer Treatment: Modern Perspectives of Ancient but Advanced Science. Cancer Medicine, 8, 1958-1975.
https://doi.org/10.1002/cam4.2108
[3] Shi, Q., Xia, F., Wang, Q., Liao, F., Guo, Q., Xu, C., et al. (2022) Discovery and Repurposing of Artemisinin. Frontiers of Medicine, 16, 1-9.
https://doi.org/10.1007/s11684-021-0898-6
[4] Efferth, T., Sauerbrey, A., Olbrich, A., Gebhart, E., Rauch, P., Weber, H.O., et al. (2003) Molecular Modes of Action of Artesunate in Tumor Cell Lines. Molecular Pharmacology, 64, 382-394.
https://doi.org/10.1124/mol.64.2.382
[5] Marchesi, E., Perrone, D. and Navacchia, M.L. (2023) Molecular Hybridization as a Strategy for Developing Artemisinin-Derived Anticancer Candidates. Pharmaceutics, 15, Article 2185.
https://doi.org/10.3390/pharmaceutics15092185
[6] Dai, X., Zhang, X., Chen, W., Chen, Y., Zhang, Q., Mo, S., et al. (2021) Dihydroartemisinin: A Potential Natural Anticancer Drug. International Journal of Biological Sciences, 17, 603-622.
https://doi.org/10.7150/ijbs.50364
[7] Adebayo, J.O., Tijjani, H., Adegunloye, A.P., Ishola, A.A., Balogun, E.A. and Malomo, S.O. (2020) Enhancing the Antimalarial Activity of Artesunate. Parasitology Research, 119, 2749-2764.
https://doi.org/10.1007/s00436-020-06786-1
[8] Tu, Y. (2011) The Discovery of Artemisinin (Qinghaosu) and Gifts from Chinese Medicine. Nature Medicine, 17, 1217-1220.
https://doi.org/10.1038/nm.2471
[9] Zhong, H., Jiang, Q., Wu, C., Yu, H.H., et al. (2024) Design, Synthesis, and Antitumor Activity Evaluation of Artemisinin Bivalent Ligands. Molecules, 29, Article 409.
https://doi.org/10.3390/molecules29020409
[10] 余和平, 崔乐, 王必蓉, 等. 青蒿素对乳腺癌MT40细胞的生长抑制作用及CD71表达的影响和后遗效应! [J]. 华中科技大学学报(医学版), 2018, 47(3): 295-299.
[11] 冯亚婵, 张皓杰, 杜朝, 等. 青蒿素通过TIGIT/CD155信号轴调控4T1乳腺癌细胞转移与凋亡[J]. 中国生物化学与分子生物学报, 2024, 40(1): 131-141.
[12] 郭海燕, 王红钰, 李晓英, 等. 青蒿素对线粒体损伤诱导的乳腺癌细胞凋亡的影响[J]. 中国临床药理学杂志, 2022, 38(6): 508-512.
[13] Cao, Y., Feng, Y.H., Gao, L.W., Li, X.Y., et al. (2019) Artemisinin Enhances the Anti-Tumor Immune Response in 4T1 Breast Cancer Cells in Vitro and in Vivo. International Immunopharmacology, 70, 110-116.
https://doi.org/10.1016/j.intimp.2019.01.041
[14] Li, J., Feng, W., Lu, H., Wei, Y., Ma, S., et al. (2019) Artemisinin Inhibits Breast Cancer-Induced Osteolysis by Inhibiting Osteoclast Formation and Breast Cancer Cell Proliferation. Journal of Cellular Physiology, 234, 12663-12675.
[15] Natesan, S., Ponnusamy, C., Sugumaran, A., Chelladurai, S., Shanmugam Palaniappan, S. and Palanichamy, R. (2017) Artemisinin Loaded Chitosan Magnetic Nanoparticles for the Efficient Targeting to the Breast Cancer. International Journal of Biological Macromolecules, 104, 1853-1859.
https://doi.org/10.1016/j.ijbiomac.2017.03.137
[16] Zhuo, Z., Zhang, D., Lu, W., Wu, X., Cui, Y., Zhang, W., et al. (2024) Reversal of Tamoxifen Resistance by Artemisinin in ER+ Breast Cancer: Bioinformatics Analysis and Experimental Validation. Oncology Research, 32, 1093-1107.
https://doi.org/10.32604/or.2024.047257
[17] 徐嘉若, 陈佳靓, 姚广涛. 基于PI3K/AKT信号通路探讨双氢青蒿素对人三阴性乳腺癌MDA-MB-231细胞增殖、凋亡的影响[J]. 上海中医药大学学报, 2021, 35(6): 49-57.
[18] Li, Y., Zhou, X., Liu, J., Gao, N., Yang, R., Wang, Q., et al. (2020) Dihydroartemisinin Inhibits the Tumorigenesis and Metastasis of Breast Cancer via Downregulating CIZ1 Expression Associated with TGF-β1 Signaling. Life Sciences, 248, Article 117454.
https://doi.org/10.1016/j.lfs.2020.117454
[19] Yao, Y., Guo, Q., Cao, Y., Qiu, Y., Tan, R., Yu, Z., et al. (2018) Artemisinin Derivatives Inactivate Cancer-Associated Fibroblasts through Suppressing TGF-β Signaling in Breast Cancer. Journal of Experimental & Clinical Cancer Research, 37, 282.
https://doi.org/10.1186/s13046-018-0960-7
[20] Li, Y., Wang, W., Li, A., Huang, W., Chen, S., Han, F., et al. (2021) Dihydroartemisinin Induces Pyroptosis by Promoting the AIM2/Caspase-3/DFNA5 Axis in Breast Cancer Cells. Chemico-Biological Interactions, 340, Article 109434.
https://doi.org/10.1016/j.cbi.2021.109434
[21] 陈镝, 吕莹, 郭怡欣, 等. 双氢青蒿素可显著增强阿霉素诱导的三阴性乳腺癌细胞凋亡: 基于负向调控STAT3/HIF-1α通路[J]. 南方医科大学学报, 2025, 45(2): 254-260.
[22] Xing, X., Zhou, Z., Farhan, M., Zhao, X., Li, S., Lei, B., et al. (2026) FoxO3a-Mediated Modulation of PD-L1 Expression and Inhibition by Dihydroartemisinin in Triple-Negative Breast Cancer. Journal of Cellular and Molecular Medicine, 30, e70947.
https://doi.org/10.1111/jcmm.70947
[23] D’Amico, S., Krasnowska, E.K., Manni, I., Toietta, G., Baldari, S., Piaggio, G., et al. (2020) DHA Affects Microtubule Dynamics through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. Cells, 9, Article 1260.
https://doi.org/10.3390/cells9051260
[24] Zhou, X., Soto-Gamez, A., Nijdam, F., Setroikromo, R. and Quax, W.J. (2022) Dihydroartemisinin-Transferrin Adducts Enhance Trail-Induced Apoptosis in Triple-Negative Breast Cancer in a P53-Independent and ROS-Dependent Manner. Frontiers in Oncology, 11, Article 789336.
https://doi.org/10.3389/fonc.2021.789336
[25] Li, Z., Zhu, Y.T., Xiang, M., Qiu, J.L., Luo, S.Q. and Lin, F. (2021) Enhanced Lysosomal Function Is Critical for Paclitaxel Resistance in Cancer Cells: Reversed by Artesunate. Acta Pharmacologica Sinica, 42, 624-632.
https://doi.org/10.1038/s41401-020-0445-z
[26] Ren, M., Liang, S., Lin, S., Huang, R., Chen, Y., Zhang, Y., et al. (2024) Design, Synthesis and Biological Evaluation of Artesunate-Se Derivatives as Anticancer Agents by Inducing GPX4-Mediated Ferroptosis. Bioorganic Chemistry, 152, Article 107733.
https://doi.org/10.1016/j.bioorg.2024.107733
[27] Zheng, D., Yan, J., Liu, X., Zhang, Z., Jin, A., Zhao, Y., et al. (2025) Artesunate Nanoplatform Targets the Serine-MAPK Axis in Cancer-Associated Fibroblasts to Reverse Photothermal Resistance in Triple-Negative Breast Cancer. Advanced Materials, 37, e2502617.
https://doi.org/10.1002/adma.202502617
[28] Terragno, M., Vetrova, A., Semenov, O., Sayan, A.E., Kriajevska, M. and Tulchinsky, E. (2024) Mesenchymal-Epithelial Transition and AXL Inhibitor TP-0903 Sensitise Triple-Negative Breast Cancer Cells to the Antimalarial Compound, Artesunate. Scientific Reports, 14, Article No. 425.
https://doi.org/10.1038/s41598-023-50710-3
[29] 梁秋实, 任卫东. 蒿甲醚对人乳腺癌细胞的增殖抑制作用研究[J]. 解剖科学进展, 2015, 21(3): 229-232.
[30] Farsam, V., Hassan, Z.M., Zavaran-Hosseini, A., Noori, S., Mahdavi, M. and Ranjbar, M. (2011) Antitumor and Immunomodulatory Properties of Artemether and Its Ability to Reduce CD4+ CD25+ FoxP3+ T Reg Cells in Vivo. International Immunopharmacology, 11, 1802-1808.
https://doi.org/10.1016/j.intimp.2011.07.008
[31] Akbarian, A., Ebtekar, M., Pakravan, N. and Hassan, Z.M. (2020) Folate Receptor Alpha Targeted Delivery of Artemether to Breast Cancer Cells with Folate-Decorated Human Serum Albumin Nanoparticles. International Journal of Biological Macromolecules, 152, 90-101.
https://doi.org/10.1016/j.ijbiomac.2020.02.106
[32] Mirzaei-Parsa, M.J., Najafabadi, M.R.H., Haeri, A., Zahmatkeshan, M., Ebrahimi, S.A., Pazoki-Toroudi, H., et al. (2020) Preparation, Characterization, and Evaluation of the Anticancer Activity of Artemether-Loaded Nano-Niosomes against Breast Cancer. Breast Cancer, 27, 243-251.
https://doi.org/10.1007/s12282-019-01014-w
[33] Gong, Y., Gallis, B.M., Goodlett, D.R., Yang, Y., et al. (2013) Effects of Transferrin Conjugates of Artemisinin and Artemisinin Dimer on Breast Cancer Cell Lines. Anticancer Research, 33, 123-132.
[34] Zhang, Y.J., Zhan, X., Wang, L., Ho, R.J.Y. and Sasaki, T. (2015) pH-Responsive Artemisinin Dimer in Lipid Nanoparticles Are Effective against Human Breast Cancer in a Xenograft Model. Journal of Pharmaceutical Sciences, 104, 1815-1824.
https://doi.org/10.1002/jps.24407
[35] Kalen, A.L., Wagner, B.A., Sarsour, E.H., Kumar, M.G., Reedy, J.L., Buettner, G.R., et al. (2020) Hydrogen Peroxide Mediates Artemisinin-Derived C-16 Carba-Dimer-Induced Toxicity of Human Cancer Cells. Antioxidants, 9, Article 108.
https://doi.org/10.3390/antiox9020108
[36] Jiang, B., Wang, J., Yue, L., Zhang, Z., Lv, J., Chen, J., et al. (2025) Anti-Tumor Effects of Artemisinin-Based Oligomers: From Monomer to Trimer as a Novel Drug-Enhancing Strategy. European Journal of Medicinal Chemistry, 287, Article 117313.
https://doi.org/10.1016/j.ejmech.2025.117313
[37] Liang, W., Liu, J., Wu, H., Qiao, X., Lu, X., Liu, Y., et al. (2019) Artemisinin Induced Reversal of EMT Affects the Molecular Biological Activity of Ovarian Cancer SKOV3 Cell Lines. Oncology Letters, 18, 3407-3414.
https://doi.org/10.3892/ol.2019.10608
[38] Li, X., Zhou, Y., Liu, Y., Zhang, X., Chen, T., Chen, K., et al. (2016) Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer. EBioMedicine, 14, 44-54.
https://doi.org/10.1016/j.ebiom.2016.11.026
[39] 刘朝霞, 王丹, 丁娇, 等. 双氢青蒿素下调Notch1蛋白表达对人卵巢癌Skov3细胞抑制作用的研究[J]. 华中科技大学学报(医学版), 2014, 43(2): 215-218.
[40] Li, X., Ba, Q., Liu, Y., Yue, Q., Chen, P., Li, J., et al. (2017) Dihydroartemisinin Selectively Inhibits PDGFRα-Positive Ovarian Cancer Growth and Metastasis through Inducing Degradation of PDGFRα Protein. Cell Discovery, 3, Article 17042.
https://doi.org/10.1038/celldisc.2017.42
[41] 茅菲, 程芳, 蒋维洪, 等. 青蒿素衍生物对卵巢癌细胞增殖和凋亡影响[J]. 中国临床药理学杂志, 2020, 36(14): 2079-2081.
[42] Liu, Y., Gao, S., Zhu, J., Zheng, Y., Zhang, H. and Sun, H. (2018) Dihydroartemisinin Induces Apoptosis and Inhibits Proliferation, Migration, and Invasion in Epithelial Ovarian Cancer via Inhibition of the Hedgehog Signaling Pathway. Cancer Medicine, 7, 5704-5715.
https://doi.org/10.1002/cam4.1827
[43] Zheng, J., Li, X., Yang, W. and Zhang, F. (2021) Dihydroartemisinin Regulates Apoptosis, Migration, and Invasion of Ovarian Cancer Cells via Mediating RECK. Journal of Pharmacological Sciences, 146, 71-81.
https://doi.org/10.1016/j.jphs.2021.02.001
[44] 陈露, 李由由, 杲飞莹, 等. 双氢青蒿素通过调节SLC7A11/GPX4信号通路诱导卵巢癌细胞铁死亡[J]. 中药材, 2024, 47(12): 3103-3107.
[45] Zhang, J., Li, Y., Wang, J.G., Feng, J.Y., Huang, G.D. and Luo, C.G. (2023) Dihydroartemisinin Affects STAT3/DDA1 Signaling Pathway and Reverses Breast Cancer Resistance to Cisplatin. The American Journal of Chinese Medicine, 51, 445-459.
https://doi.org/10.1142/s0192415x23500234
[46] Wei, Y., Liu, F., Zhu, X., Liu, X., Li, H., Hou, L., et al. (2025) Artesunate Disrupts Ribosome RNA Biogenesis and Inhibits Ovarian Cancer Growth by Targeting FANCA. Phytomedicine, 136, Article 156333.
https://doi.org/10.1016/j.phymed.2024.156333
[47] Li, J., Feng, L., Yuan, Y., He, T., Zou, X., Su, B., et al. (2024) Inhibition of HOXC11 by Artesunate Induces Ferroptosis and Suppresses Ovarian Cancer Progression through Transcriptional Regulation of the PROM2/PI3K/AKT Pathway. World Journal of Surgical Oncology, 22, Article No. 268.
https://doi.org/10.1186/s12957-024-03544-w
[48] Li, B., Bu, S., Sun, J., Guo, Y. and Lai, D. (2018) Artemisinin Derivatives Inhibit Epithelial Ovarian Cancer Cells via Autophagy-Mediated Cell Cycle Arrest. Acta Biochimica et Biophysica Sinica, 50, 1227-1235.
https://doi.org/10.1093/abbs/gmy125
[49] Wang, B., Hou, D., Liu, Q., Wu, T., Guo, H., Zhang, X., et al. (2015) Artesunate Sensitizes Ovarian Cancer Cells to Cisplatin by Downregulating RAD51. Cancer Biology & Therapy, 16, 1548-1556.
https://doi.org/10.1080/15384047.2015.1071738
[50] 陈晓, 高英芳, 张志敏, 等. 青蒿琥酯逆转人卵巢癌3AO细胞所致T淋巴细胞的免疫抑制研究[J]. 重庆医学, 2018, 47(24): 3142-3145.
[51] Nie, D., Zhang, H., Wang, H., Song, W., Yuan, D., Zhu, D., et al. (2025) Artesunate Triggers Ferroptosis in Ovarian Cancer via GP130-Mediated IL-6/STAT3/OTUB1/SLC711 Axis Disruption. Phytomedicine, 148, Article 157269.
https://doi.org/10.1016/j.phymed.2025.157269
[52] 冯露, 袁怡君, 李均, 等. 青蒿琥酯通过抑制TEAD2/RRM2轴诱导卵巢癌细胞铁死亡[J]. 现代肿瘤医学, 2025, 33(11): 1870-1881.
[53] Li, J., Feng, L., Yuan, Y., He, T., Zou, X., Su, B., et al. (2024) Inhibition of HOXC11 by Artesunate Induces Ferroptosis and Suppresses Ovarian Cancer Progression through Transcriptional Regulation of the PROM2/PI3K/AKT Pathway. World Journal of Surgical Oncology, 22, Article No. 268.
https://doi.org/10.1186/s12957-024-03544-w
[54] Koike, T., Takenaka, M., Suzuki, N., Ueda, Y., Mori, M., Hirayama, T., et al. (2022) Intracellular Ferritin Heavy Chain Plays the Key Role in Artesunate-Induced Ferroptosis in Ovarian Serous Carcinoma Cells. Journal of Clinical Biochemistry and Nutrition, 71, 34-40.
https://doi.org/10.3164/jcbn.21-82
[55] Hao, D.L., Xie, R., De, G.J., Yi, H., et al. (2020) pH-Responsive Artesunate Polymer Prodrugs with Enhanced Ablation Effect on Rodent Xenograft Colon Cancer. International Journal of Nanomedicine, 15, 1771-1786.
https://doi.org/10.2147/ijn.s242032
[56] Li, G., Ling, M., Yu, K., Yang, W., Liu, Q., He, L., et al. (2022) Synergetic Delivery of Artesunate and Isosorbide 5-Mononitrate with Reduction-Sensitive Polymer Nanoparticles for Ovarian Cancer Chemotherapy. Journal of Nanobiotechnology, 20, Article No. 471.
https://doi.org/10.1186/s12951-022-01676-3
[57] 谭先杰, 郎景和, 沈铿, 等. 青蒿素及其衍生物蒿甲醚的体外抗卵巢癌作用及其机制探讨[C]//中华医学会. 第八次全国妇产科学学术会议论文汇编. 2004: 231.
[58] Mondal, A. and Chatterji, U. (2015) Artemisinin Represses Telomerase Subunits and Induces Apoptosis in HPV-39 Infected Human Cervical Cancer Cells. Journal of Cellular Biochemistry, 116, 1968-1981.
https://doi.org/10.1002/jcb.25152
[59] 刘玉琼. 青蒿素通过PI3K/Akt/mTOR信号通路影响宫颈癌细胞的迁移和凋亡[J]. 现代妇产科进展, 2020, 29(2): 144-146.
[60] Fan, Q.Q., Qin, H.F. and Liu, Y.Q. (2026) Artemisinin Inhibits Drug Resistance and Epithelial-Mesenchymal Transition in Cervical Cancer Cells via the Wnt/β-Catenin Signaling Pathway. Bulletin of Experimental Biology and Medicine, 179, 636-643.
https://doi.org/10.1007/s10517-026-06540-0
[61] 陶敏, 杨兰香, 潘俊杰, 等. 基于网络药理学和分子对接技术探究青蒿素对宫颈癌的潜在治疗机制及初步验证[J]. 齐齐哈尔医学院学报, 2024, 45(21): 2001-2006.
[62] 杨华, 谭先杰, 郎景和, 等. 青蒿素衍生物对宫颈癌HeLa细胞体外增殖及凋亡能力的影响及其分子机制研究[J]. 现代妇产科进展, 2017, 26(12): 881-884.
[63] 纪蓉. 青蒿琥酯对人宫颈癌HeLa和Siha细胞放射敏感性的影响及作用机制研究[D]: [硕士学位论文]. 苏州: 苏州大学, 2010.
[64] Trimble, C.L., Levinson, K., Maldonado, L., Donovan, M.J., Clark, K.T., Fu, J., et al. (2020) A First-in-Human Proof-of-Concept Trial of Intravaginal Artesunate to Treat Cervical Intraepithelial Neoplasia 2/3 (CIN2/3). Gynecologic Oncology, 157, 188-194.
https://doi.org/10.1016/j.ygyno.2019.12.035
[65] Sadana, A., Omoto, J., Sorgi, K., Rahangdale, L., Smith, J.S., Plesa, M., et al. (2025) Feasibility of Intravaginal Artesunate as an Adjuvant HPV & Cervical Precancer Treatment among Women Living with HIV in Kenya: Study Protocol for a Phase II Clinical Trial. Cancer Control, 32, Article 10732748251374418.
https://doi.org/10.1177/10732748251374418
[66] Erickson, B.K., Slomovitz, B., Powell, M. and Eskander, R.N. (2024) Top Advances of the Year: Uterine Cancer. Cancer, 130, 2409-2412.
https://doi.org/10.1002/cncr.35321
[67] Yin, X.H., Liu, Y., Qin, J.R., et al. (2021) Artesunate Suppresses the Proliferation and Development of Estrogen Receptor-α-Positive Endometrial Cancer in HAND2-Dependent Pathway. Frontiers in Cell and Developmental Biology, 8, Article 606969.
https://doi.org/10.3389/fcell.2020.606969
[68] Zhu, Y., Klausen, C., Zhou, J., Guo, X., Zhang, Y., Zhu, H., et al. (2019) Novel Dihydroartemisinin Dimer Containing Nitrogen Atoms Inhibits Growth of Endometrial Cancer Cells and May Correlate with Increasing Intracellular Peroxynitrite. Scientific Reports, 9, Article No. 15528.
https://doi.org/10.1038/s41598-019-52108-6
[69] 周洁芸, 李国停, 马阿影, 等. SM1052对人子宫内膜癌(RL95-2) p53信号通路的影响[C]//中国药理学会生殖药理学专业委员会. 中国药理学会第九届全国基础与临床生殖药理学术研讨会论文汇编. 2015: 48.
[70] 周洁芸, 李钊, 文捷, 等. 新型青蒿素二聚体衍生物SM1039抗人子宫内膜癌(RL95-2)的实验研究[C]//中国药理学会生殖药理学专业委员会. 中国药理学会第十届全国基础与临床生殖药理学术研讨会暨2017育英生殖药理论坛论文汇编. 2017: 48-49.